Droplet based screening of molecular libraries in a microfluidic device

微流体装置中分子库的基于液滴的筛选

• 批准号: 7793556
• 负责人: DARREN R LINK
• 金额: $ 34.86万
• 依托单位: RAINDANCE TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-21 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7793556
• 关键词: Applications Grants; Biological Assay; Biological Sciences; Biology; Blood capillaries; Budgets; Businesses; Cells; Cellular Assay; Chemistry; Collection; Communities; Cost Savings; DNA; Development; Dose; Encapsulated; Engineering; Enzymes; Funding; Goals; Grant; In Vitro; Laboratories; Libraries; Liquid substance; Methodology; Microfluidic Microchips; Microfluidics; Microscopic; Miniaturization; Molecular; Molecular Bank; Pharmacologic Substance; Pharmacology; Phase; Preclinical Drug Evaluation; Preparation; Process; Progress Reports; Proteins; Reaction; Reagent; Recombinants; Research; Research Infrastructure; Research Methodology; Robotics; Sampling; Screening procedure; Specificity; System; Technology; Testing; Time; Tube; United States National Institutes of Health; Work; base; capillary; commercialization; cost; design; established cell line; evaporation; high throughput screening; improved; instrument; member; milliliter; operation; programs; public health relevance; research study; response; small molecule; surfactant

DESCRIPTION (provided by applicant): In Phase II we will continue the development of RainDance Technologies droplet-based microfluidic instrument platform, based on the results from the Phase I proof-of-principle experiments, and develop a commercial system that includes the ability to screen compound libraries in droplets. Our goal by the end of Phase II will be to provide a complete instrument platform able to screen a compound library composed of up to 100,000 members using assays for both a recombinant enzyme and an established cell line. Initial efforts will focus on compound management and handling of barcoded droplets, additional effort will fully enable microfluidic assays and disposable chip designs, and we will complete the integration and engineering development for commercialization before the end of the two year grant period. We believe that significant value to the research and pharmaceutical communities will result from complete development of a droplet-based open platform, specifically for the use of high throughput screening (HTS) formatted droplet libraries with fluorescent in vitro protein and cellular assays. PUBLIC HEALTH RELEVANCE: Miniaturization of laboratory operations in biology and chemistry has reduced reaction volumes from a few milliliters (in test-tubes) to a few microliters (in microtiter plates) - a 1000-fold reduction. The drive to increase throughput by assay miniaturization has been particularly important for drug screening. Today, many industrial screening programs process 100,000 compounds a day (~1 per second), a thousand times as many as were processed in an entire week in 1990. Although robotic microtiter plate based infrastructure has enabled the screening of collections exceeding one million small molecules, the primary screening methodology has largely been restricted to assaying a single high concentration of each compound. Further reducing test volumes below the 1-2 <l capacity of 1536-well plates would create both significant cost savings and enable higher throughput. Furthermore, a primary screen that included a dose-response curve for every compound, for example, would significantly reduce the number of false positives and false negatives compared to a single-point screen, and are able to identify subtle pharmacologies such as partial agonism or antagonism. In addition, it should also be possible to screen each compound simultaneously against multiple targets to determine specificity. However, using microtiter plate technology for further miniaturization is problematic: for example, evaporation becomes significant in microliter volumes, capillary action causes "wicking" and bridging of liquid between wells, and this would not alleviate the time and consumables cost associated with robotic microtiter plate handling. The key technology in this proposal is RainDance Technologies' droplet-based microfluidic platform. Using this platform, we believe we can further reduce the volume of each assay by 103- to 106-fold and increase the throughput >1,000 times, by confining each assay in a separate microscopic droplet. We will use this technology to enable high throughput screening for molecular and cell-based assays, significantly reducing the cost, time, and reagents for screening, and enabling the prospect of high throughput primary cell screening.

描述（由申请人提供）：在第二阶段，我们将根据第一阶段原理验证实验的结果，继续开发RainDance Technologies基于液滴的微流控仪器平台，并开发一个商业系统，包括筛选液滴中的化合物库的能力。我们的目标是在II期结束时提供一个完整的仪器平台，能够使用重组酶和已建立的细胞系的检测来筛选由多达100,000个成员组成的化合物库。最初的努力将集中在化合物管理和条形码液滴的处理上，额外的努力将完全实现微流控分析和一次性芯片设计，我们将在两年的资助期结束前完成集成和商业化的工程开发。我们相信，基于液滴的开放平台的完整开发，特别是高通量筛选（HTS）格式的液滴库与荧光体外蛋白质和细胞分析的使用，将对研究和制药界产生重大价值。公共卫生相关性：生物和化学实验室操作的小型化使反应体积从几毫升（试管）减少到几微升（微量滴度板）——减少了1000倍。通过分析小型化来提高通量的驱动对于药物筛选尤其重要。今天，许多工业筛选程序每天处理10万种化合物（每秒约1种），是1990年一周处理量的1000倍。尽管基于机器人微滴板的基础设施已经能够筛选超过一百万个小分子的集合，但主要的筛选方法在很大程度上仅限于分析单个高浓度的每种化合物。进一步将测试量减少到1536孔板的1-2 <l容量以下，既可以显著节省成本，又可以实现更高的产量。此外，包括每种化合物的剂量-反应曲线的初级筛选，例如，与单点筛选相比，将显著减少假阳性和假阴性的数量，并且能够识别微妙的药理学，如部分激动作用或拮抗作用。此外，还应该有可能同时针对多个靶点筛选每种化合物以确定特异性。然而，使用微滴板技术进一步小型化是有问题的：例如，在微升体积中，蒸发变得很重要，毛细管作用导致“吸干”和井间液体桥接，这不会减轻机器人微滴板处理相关的时间和耗材成本。该方案的关键技术是RainDance Technologies基于液滴的微流控平台。使用这个平台，我们相信我们可以通过将每个检测限制在一个单独的微滴中，将每个检测的体积进一步减少103- 106倍，并将通量提高1000倍。我们将使用该技术实现分子和细胞检测的高通量筛选，显著降低筛选的成本、时间和试剂，并使高通量原代细胞筛选成为可能。